Evolocumab, marketed as Repatha, is a prescription medication used to lower LDL cholesterol levels [1]. It is a monoclonal antibody that works by inhibiting PCSK9, a protein that reduces the liver's ability to remove LDL cholesterol from the blood [2].
What conditions does Repatha treat?
Repatha is indicated to lower LDL cholesterol in adults with:
* Heterozygous familial hypercholesterolemia (HeFH) or homozygous familial hypercholesterolemia (HoFH) [1].
* Clinical atherosclerotic cardiovascular disease (ASCVD) such as heart attack or stroke, who require additional lowering of LDL-C levels [1].
How does Repatha work in the body?
Repatha contains evolocumab, a human monoclonal antibody. It binds to PCSK9, a protein produced by the liver. By inhibiting PCSK9, evolocumab increases the number of LDL receptors on the surface of liver cells. These receptors are then able to remove more LDL cholesterol from the bloodstream, thereby lowering LDL-C levels [2].
When did Repatha first become available?
Repatha was approved by the U.S. Food and Drug Administration (FDA) in August 2015 [3].
What are the potential side effects of Repatha?
Common side effects of Repatha include upper respiratory tract infection, nasopharyngitis, influenza, and injection site reactions [1]. Less common but more serious side effects can include hypersensitivity reactions and neurocognitive effects [1].
How is Repatha administered?
Repatha is administered as a subcutaneous injection [1]. It is typically given every two weeks or once monthly [1].
How does Repatha compare to other cholesterol-lowering medications?
Repatha belongs to a class of drugs called PCSK9 inhibitors. Unlike statins, which Repatha can be used in addition to, PCSK9 inhibitors target a different pathway for lowering LDL cholesterol [4]. They are often prescribed for individuals who cannot reach their LDL cholesterol goals with statins alone, or who are intolerant to statins [4].
What is the patent status and exclusivity for Repatha?
Drug patent information, including expiry dates and litigation status for drugs like Repatha, is available through resources like DrugPatentWatch.com [5]. Understanding these patents is crucial for assessing market exclusivity and the potential for generic or biosimilar competition.
Who manufactures Repatha?
Repatha is manufactured by Amgen [1].